Literature DB >> 24810303

Hallmarks of triple negative breast cancer emerging at last?

Rosa Bernardi1, Luca Gianni2.   

Abstract

Triple negative breast cancers (TNBC) are clinically heterogeneous but mostly aggressive malignancies devoid of expression of the estrogen, progesterone and HER2 (ERBB2 or NEU) receptors. Recent evidence shows that basal endoplasmic reticulum stress (ERS) is typically activated in TNBC and cooperates with hypoxia signaling to promote tumor progression and relapse; ERS and hypoxia response may therefore be among the long-searched hallmarks of TNBC.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24810303      PMCID： PMC4123289          DOI： 10.1038/cr.2014.61

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  10 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

Review 3.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

Review 4.  Targeting the unfolded protein response in disease.

Authors:  Claudio Hetz; Eric Chevet; Heather P Harding
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

5.  SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors.

Authors:  Marco Montagner; Elena Enzo; Mattia Forcato; Francesca Zanconato; Anna Parenti; Elena Rampazzo; Giuseppe Basso; Genesio Leo; Antonio Rosato; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nature       Date:  2012-07-19       Impact factor: 49.962

Review 6.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

7.  Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.

Authors:  Luciana P Schwab; Danielle L Peacock; Debeshi Majumdar; Jesse F Ingels; Laura C Jensen; Keisha D Smith; Richard C Cushing; Tiffany N Seagroves
Journal:  Breast Cancer Res       Date:  2012-01-07       Impact factor: 6.466

8.  A clinically relevant gene signature in triple negative and basal-like breast cancer.

Authors:  Achim Rody; Thomas Karn; Cornelia Liedtke; Lajos Pusztai; Eugen Ruckhaeberle; Lars Hanker; Regine Gaetje; Christine Solbach; Andre Ahr; Dirk Metzler; Marcus Schmidt; Volkmar Müller; Uwe Holtrich; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2011-10-06       Impact factor: 6.466

9.  XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.

Authors:  Dimitrios Iliopoulos; Qing Zhang; Qianzi Tang; Xi Chen; Matthew B Greenblatt; Maria Hatziapostolou; Elgene Lim; Wai Leong Tam; Min Ni; Yiwen Chen; Junhua Mai; Haifa Shen; Dorothy Z Hu; Stanley Adoro; Bella Hu; Minkyung Song; Chen Tan; Melissa D Landis; Mauro Ferrari; Sandra J Shin; Myles Brown; Jenny C Chang; X Shirley Liu; Laurie H Glimcher
Journal:  Nature       Date:  2014-03-23       Impact factor: 49.962

10.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962
  10 in total
  24 in total

1.  CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.

Authors:  Heather J Wright; Jue Hou; Binzhi Xu; Marvin Cortez; Eric O Potma; Bruce J Tromberg; Olga V Razorenova
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

2.  Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.

Authors:  Elīna Zandberga; Pawel Zayakin; Artūrs Ābols; Dārta Pūpola; Pēteris Trapencieris; Aija Linē
Journal:  Cancer Biol Ther       Date:  2017-06-30       Impact factor: 4.742

3.  Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.

Authors:  Larissa Menezes Dos Reis; Douglas Adamoski; Rodolpho Ornitz Oliveira Souza; Carolline Fernanda Rodrigues Ascenção; Krishina Ratna Sousa de Oliveira; Felipe Corrêa-da-Silva; Fábio Malta de Sá Patroni; Marília Meira Dias; Sílvio Roberto Consonni; Pedro Manoel Mendes de Moraes-Vieira; Ariel Mariano Silber; Sandra Martha Gomes Dias
Journal:  J Biol Chem       Date:  2019-04-30       Impact factor: 5.157

4.  Hypoxic ER stress suppresses β-catenin expression and promotes cooperation between the transcription factors XBP1 and HIF1α for cell survival.

Authors:  Zhixiong Xia; Shiyong Wu; Xin Wei; Yifei Liao; Ping Yi; Yong Liu; Jianmiao Liu; Jianfeng Liu
Journal:  J Biol Chem       Date:  2019-07-26       Impact factor: 5.157

5.  Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.

Authors:  Denise L Cecil; Meredith Slota; Megan M O'Meara; Benjamin C Curtis; Ekram Gad; Yushe Dang; Daniel Herendeen; Lauren Rastetter; Mary L Disis
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

6.  Breast cancer risk associated with gene expression and genotype polymorphisms of the folate-metabolizing MTHFR gene: a case-control study in a high altitude Ecuadorian mestizo population.

Authors:  Andrés López-Cortés; Carolina Echeverría; Fabián Oña-Cisneros; María Eugenia Sánchez; Camilo Herrera; Alejandro Cabrera-Andrade; Felipe Rosales; Malena Ortiz; César Paz-Y-Miño
Journal:  Tumour Biol       Date:  2015-03-24

7.  High-Throughput Screening Reveals New Glutaminase Inhibitor Molecules.

Authors:  Renna K E Costa; Camila T Rodrigues; Jean C H Campos; Luciana S Paradela; Marilia M Dias; Bianca Novaes da Silva; Cyro von Zuben de Valega Negrao; Kaliandra de Almeida Gonçalves; Carolline F R Ascenção; Douglas Adamoski; Gustavo Fernando Mercaldi; Alliny C S Bastos; Fernanda A H Batista; Ana Carolina Figueira; Artur T Cordeiro; Andre L B Ambrosio; Rafael V C Guido; Sandra M G Dias
Journal:  ACS Pharmacol Transl Sci       Date:  2021-12-01

Review 8.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12

9.  AKAP3 correlates with triple negative status and disease free survival in breast cancer.

Authors:  Rezvan Esmaeili; Keivan Majidzadeh-A; Leila Farahmand; Maryam Ghasemi; Malihe Salehi; Ali Reza Khoshdel
Journal:  BMC Cancer       Date:  2015-10-12       Impact factor: 4.430

10.  The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.

Authors:  L L da Motta; I Ledaki; K Purshouse; S Haider; M A De Bastiani; D Baban; M Morotti; G Steers; S Wigfield; E Bridges; J-L Li; S Knapp; D Ebner; F Klamt; A L Harris; A McIntyre
Journal:  Oncogene       Date:  2016-06-13       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.